La cadena de opciones muestra datos clave de las opciones de acciones de Immix Biopharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Immix Biopharma..

Immix Biopharma (NASDAQ:IMMX) Bolsa, Cadena de Opciones

IMMIX BIOPHARMA INC

Immix Biopharma

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Mercados

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATNF

BDRX

DECK

HNRG

IMMX

INEO

INTU

LITM

LTBR

MLGO

MNSO

OKLO

ROST

SGBX

SOBR

VTAK

Intuit sorprende al mercado con ingresos y BPA mejores de lo esperado. Revisa los mayores ganadores y perdedores del premercado.

Las acciones de Intuit (INTU) cotizan un 8% más alto; Aquí están 20 acciones que se mueven en el premercado

WIIM

WLGS

Wang & Lee Group shares are trading lower after the company announced a 250-to-1 share consolidation.

ZOOZ

ZOOZ Power shares are trading lower. The company announced a $180 million private placement to launch a Bitcoin treasury reserve strategy.

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Bakkt Holdings shares are trading lower after the company announced a $75 million public offering.

AstraZeneca Plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $14.07 billion</a>, driven by double-digit growth in oncology and biopharmaceuticals.
The company's adjusted EPADS&nbsp;reached&nbsp;$1.08, missing the consensus of $1.10. The adjusted EPS was $2.17 (1 ADR = 2 Common Shares).
Also Read: <a href="https://www.benzinga.com/news/health-care/25/07/46555155/trump-tariffs-forces-astrazeneca-to-bring-substantial-pharmaceutical-production-to-us" target="_blank" rel="noreferrer noopener">Trump Tariffs Force AstraZeneca To Bring Substantial Pharmaceutical Production To US</a>
AstraZeneca's top business, oncology (cancer), accounted for 44% of total sales. It <a href="https://www.astrazeneca.com/content/dam/az/PDF/2025/h1q2/H1-and-Q2-2025-results-announcement.pdf" target="_blank" rel="noreferrer noopener">increased</a> 18% (up 18% on constant currency) to $6.31 billion.
<ul class="wp-block-list">
<li>Tagrisso sales were up 13% to $1.81 billion (12% at CER), Imfinzi revenues were up 27% (+26%) to $1.46 billion, Calquence sales increased 10% to $872 million, Lynparza sales increased 13% (+11%) to $838 million, and Enhertu revenue was up 41% (42% at CER) to $666 million.</li>
<li>On Monday, the Food and Drug Administration (FDA)&nbsp;<a href="https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-granted-priority-review-and-breakthrough-therapy-designation-us-patients-with-resectable-early-stage-gastric-gastroesophageal-junction-cancers.html" target="_blank" rel="noreferrer noopener">accepted</a> and granted Priority Review in the U.S. for AstraZeneca's supplemental Biologics License Application for Imfinzi (durvalumab) for resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers.</li>
<li>The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the fourth quarter of 2025.</li>
</ul>
Cardiovascular, renal, and metabolism (CVRM) sales accounted for 23%, which increased by 3% (up 3% at CER) to&nbsp;$3.64 billion.
<ul class="wp-block-list">
<li>The largest selling drug in the segment, Farxiga, accounted for 15% of sales. </li>
<li>It was up 11% (10% at CER) to $2.15 billion.</li>
</ul>
Respiratory &amp; Immunology (R&amp;I) sales increased 13% (12% CER) to $2.15 billion.
<ul class="wp-block-list">
<li>Symbicort revenues fell 1% (-1% CER) to $715 million, and Fasenra sales increased 19% (+18%) to $502 million.</li>
</ul>
Rare Disease drug sales increased by 7% to&nbsp;$2.94 billion.
<ul class="wp-block-list">
<li>Ultomiris sales were up 25% (23% at CER) to $1.18 billion, offset by a 24% decline in Soliris (-22% at CER) to $530 million.</li>
</ul>
China's sales accounted for 12% of quarterly sales, up 5% on a reported basis to&nbsp;$1.71 billion (+5% at CER).
Pascal Soriot, CEO of AstraZeneca, <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/h1-and-q2-2025.html" rel="noreferrer noopener">commented</a> on Tuesday, "Our strong momentum in revenue growth continued through the first half of the year, and the delivery from our broad and diverse pipeline has been excellent, with 12 positive key Phase III trial readouts, including for&nbsp;baxdrostat,&nbsp;gefurulimab, and&nbsp;Tagrisso, in just the past few weeks.&#8221;
Guidance:&nbsp;For fiscal year 2025, AstraZeneca <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45069668/astrazeneca-q1-sales-and-earnings-rise-warns-china-import-tax-could-be-up-to-8-million-ceo-says-tariff-related-exposure-limited" rel="noreferrer noopener">reaffirms total revenue</a> to increase by a high single-digit percentage and core EPS to increase by a low double-digit percentage.
Pipeline Update: AstraZeneca removed three phase 1 underdevelopment assets from its pipeline, including:
<ul class="wp-block-list">
<li>AZD5851 GPC3 CAR-T hepatocellular carcinoma</li>
<li>AZD6422 CLDN18.2 CAR-T solid tumors.</li>
<li>NT-125 autologous, fully-individualised, multi-specific TCR-T targeting neoantigens in solid tumors.</li>
</ul>
The company also <a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2025/h1q2/H1-and-Q2-2025-results-clinical-trials-appendix.pdf" rel="noreferrer noopener">removed</a> an additional indication for zibotentan/dapagliflozin, an endothelin A receptor antagonist/SGLT2 inhibitor, for liver cirrhosis.
Price Action: AZN stock is up 2.60% at $73.70&nbsp;during the premarket session at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46678476/sony-files-federal-lawsuit-against-tencent-claims-upcoming-game-light-of-motiram-rips-off-horizons-story-gameplay-and-art" target="_blank" rel="noreferrer noopener">Sony Files Federal Lawsuit Against Tencent, Claims Upcoming Game &#8216;Light Of Motiram&#8217; Rips Off Horizon&#8217;s Story, Gameplay And Art</a></li>
</ul>
Image: Shutterstock

Biotech

Earnings

Large Cap

Guidance

Health Care

General

AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook

STAI

ScanTech AI Systems shares are trading higher after the company announced it will offer its technology through the TIPS contract it entered with Creeksource Consulting.

Trading Halt: Halt status updated at 9:45:00 AM ET: Quotation Resumption: News and Resumption Times

Raymond James analyst Alexander Sklar reiterates Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) with a Outperform and raises the price target from $32 to $35.

Price Target

Reiteration

Analyst Ratings

NCNO

Raymond James Reiterates Outperform on Ncino, Raises Price Target to $35

A U.S.-based startup called Farnsworth Intelligence is offering access to stolen <a href="https://www.benzinga.com/opinion/25/06/45972474/transforming-personal-data-into-profit-through-ai">personal data</a>, including passwords, addresses, autofill data, and browser history, for as little as $50,<a href="https://www.404media.co/a-startup-is-selling-data-hacked-from-peoples-computers-to-debt-collectors/"> 404 Media</a> reports.
The founder of Farnsworth Intelligence, 23‑year‑old Aidan Raney, markets the service under a product named Infostealers, positioning it as "open‑source intelligence." According to 404 Media, buying the $50 package grants access to a searchable database covering millions of devices.
The service claims to collect data extracted from malware known as "infostealers," which steal usernames, passwords, crypto wallet details, billing info, and browsing logs. Farnsworth reportedly aggregates data from more than 50 million infected computers, 404 Media says.
Don't Miss:
<ul class="wp-block-list">
<li>Be part of the breakthrough that could replace plastic as we know it—<a href="https://www.benzinga.com/money/timeplast-advertorial">invest in Timeplast before the July 31st deadline and help revolutionize a $1.3T industry.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
<h2 class="wp-block-heading">Who Uses Infostealer Data and How It's Marketed</h2>
404 Media reports that Farnsworth sells this data to a variety of industries, including <a href="https://www.benzinga.com/personal-finance/management/25/07/46381287/debt-has-dictated-job-choice-for-some-37-of-people-according-to-zety-survey">debt</a> collectors, divorce professionals, and companies seeking competitor customer leads. These use cases are outlined on its site or reported by journalists as part of its marketing messages.
According to the report, Farnsworth Intelligence represents a change in how some companies approach open-source intelligence. Traditional open-source intelligence has typically involved information already available to the public, such as social media profiles or flight records. Today, some firms are incorporating data taken from personal or corporate devices and posted online, creating platforms that organize and sell this information for a variety of uses.
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can <a href="https://www.benzinga.com/money/mode-mobile-2">invest today for just $0.30/share.</a>
<h2 class="wp-block-heading">Data Reach and Volume: Scale of Farnsworth's Dataset</h2>
Farnsworth Intelligence says on its<a href="https://www.farnsworthintelligence.com/"> website</a> that it leverages infostealer logs, along with data from breaches, leaks, open file servers, public records, and even unlisted cloud files, to assemble its datasets. Its intelligence platform uses multiple sources, including dark web scraping, social engineering, human intelligence, and freedom of information act requests to build a vast dataset.
404 Media reports that Farnsworth claims to pull data from more than 50 million computers infected with infostealer malware, consolidating passwords, cookies, browser history, and autofill data into its platform. The public portal offers searchable records for a wide range of victims, enabling users to query by email, username, or billing info.
On its website, Farnsworth promotes itself as an elite open-source intelligence provider offering corporate due diligence, privacy audits, background checks, and advanced asset searches. The startup emphasizes that it uses trillions of data points, combining clearweb, deepweb, and darkweb sources to support intelligence reports.&nbsp;
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
<h2 class="wp-block-heading">A Powerful OSINT Tool</h2>
Farnsworth Intelligence positions Infostealer data platform as a next-level open-source intelligence resource, with fluency in extracting data from infostealer malware, social media leaks, open servers, and public records. The startup&#8217;s site lists use by compliance teams, intelligence analysts, cybersecurity professionals, and corporate investigators seeking deep digital footprint analysis.
The company claims a high level of technical capability, offering Cellebrite and Magnet Axiom forensic services, human intelligence operations, and custom data feeds or application programming interface access to clients. Farnsworth presents client testimonials praising thoroughness, professionalism, and successful intelligence outcomes.
<h2 class="wp-block-heading">Accessible For $50: Risks From Minimal Vetting and Broad Use Cases</h2>
Farnsworth Intelligence's Infostealer service breaks from traditional open-source intelligence by packaging infostealer-derived personal data into a consumer-accessible platform. With a low entry price, the platform brands itself as a pioneering data intelligence tool.
Read Next: Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora &amp; MGM—<a href="https://www.benzinga.com/money/rad-intel">Just $0.63 Before NASDAQ Launch</a>
Image: Shutterstock

For Just $50, This U.S. Data Broker Will Sell Your Stolen Passwords, Addresses, and Browsing History—No Questions Asked

AIM ImmunoTech shares are trading lower after the company announced a $8 million public offering consisting of shares as well as class E and F warrants.

<a href="https://www.bloomberg.com/news/articles/2025-07-29/primary-dealers-expect-steady-treasury-auction-sizes-for-quarter?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-29/primary-dealers-expect-steady-treasury-auction-sizes-for-quarter?embedded-checkout=true</a>

'Primary Dealers Expect Steady Treasury Auction Sizes for Quarter'- Bloomberg

Norfolk Southern Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) reported financial results for the second quarter ahead of the market open on Tuesday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/07/n46683047/norfolk-southern-reports-second-quarter-2025-results">from the quarter</a>.
Q2 Earnings: Norfolk Southern reported second-quarter revenue of $3.11 billion, beating analyst estimates of $3.10 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported second-quarter adjusted earnings of $3.29 per share, beating analyst estimates of $3.27 per share.
Railway operating revenues were up $66 million year-over-year to&nbsp;$3.1 billion on volume growth of&nbsp;3%. Excluding the impact of fuel surcharge revenue, railway revenue was up 4% year-over-year. 
&#8220;This quarter, Norfolk Southern delivered another set of strong results — growing volumes, managing costs, and delivering&nbsp;8%&nbsp;EPS growth. While we remain clear-eyed about market uncertainty, our performance reflects the strength of our strategy and our ability to continue disciplined execution, relentless focus on safety and seamless customer service,&#8221; said Mark George, president and CEO&nbsp;of Norfolk Southern.
Guidance: Norfolk Southern expects full-year 2025 revenue growth of 3% to 4% compared to 2024. The company anticipates an improvement of 100 to 150 basis points in adjusted operating ratio for 2025, but said it expects the third quarter to be pressured due to weaker revenue than expected early in the quarter.
Norfolk Southern now expects productivity savings in 2025 of over $175 million due to strong results from cost-control measures. 
Norfolk Southern also announced an agreement with Union Pacific Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) to combine in a stock and cash transaction. Union Pacific will acquire Norfolk Southern at an implied value of $320 per share. Shareholders are set to receive one share of Union Pacific and $88.82 in cash for each share of Norfolk Southern stock held.&nbsp;The deal will create America&#8217;s first transcontinental railroad.
NSC Price Action: <a href="http://benzinga.com/quote/NSC" target="_blank" rel="noreferrer noopener">Norfolk Southern shares</a> were down 1.58% at $281.89 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/07/46644138/deal-dispatch-will-buffett-catch-the-train-plus-bezos-circles-cnbc">Deal Dispatch: Will Buffett Catch The Train? Plus — Bezos Circles CNBC</a></li>
</ul>
Photo: Ian Dewar Photography/Shutterstock.com

Norfolk Southern Q2 Earnings: Revenue, EPS Beat Estimates, Company Flags 'Weaker' Revenue Early In Q3

BRSL

Brightstar Lottery shares are trading higher after the company reported better-than-expected Q2 sales results.

Eagle Materials shares are trading higher after the company reported better-than-expected Q1 financial results.

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) reported second-quarter 2025 earnings on Tuesday and <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46672190/unitedhealth-group-shares-flat-ahead-of-earnings-as-market-awaits-guidance" rel="noreferrer noopener">reestablished its 2025 guidance</a>.
The insurance giant reported adjusted earnings of $4.08, down from $6.80 a year ago, missing the consensus of $4.95.
Revenues increased 13% year over year to $111.62 billion, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of $111.69 billion</a>.
"UnitedHealth Group has embarked on a rigorous path back to being a high-performing company&#8230;," said UnitedHealth CEO Stephen Hemsley. The company is strengthening operating disciplines, positioning itself for <a href="https://www.benzinga.com/pressreleases/25/07/b46681310/unitedhealth-group-re-establishes-full-year-outlook-and-reports-second-quarter-2025-results" target="_blank" rel="noreferrer noopener">growth in 2026 and beyond</a>, he added.
Also Read: <a href="https://www.benzinga.com/news/legal/25/07/46605691/unitedhealth-under-federal-scrutiny-reaffirms-integrity-of-its-medicare-operations" target="_blank" rel="noreferrer noopener">UnitedHealth Under Federal Scrutiny—Reaffirms Integrity Of Its Medicare Operations</a>
In addition:
<ul class="wp-block-list">
<li>Q2 medical care ratio of 89.4% increased 430 basis points year-over-year.</li>
<li>Operating cost ratio was 12.3% compared to 13.3% in the year-ago quarter reflecting business mix, inclusive of the Part D program changes, reduced impacts from last year's Change Healthcare cyberattack and cost management activities.</li>
<li>Q2 revenue was $86.1 billion, a 17% year-over-year boost. </li>
<li>The segment served 50 million people, an increase of 770,000 year-to-date.</li>
<li>Earnings from operations were $2.1 billion compared to $4.0 billion in the second quarter of 2024, and the margin fell from 5.4% to 2.4% primarily due to higher-than-expected medical cost trends across the UnitedHealthcare businesses and the effects of the Medicare funding reductions.</li>
<li>For the employer and individual segment, the number of people served increased by 400,000 year-over-year, with growth in employer self-funded offerings of 695,000 partially offset by attrition in both individual and group fully insured products.</li>
<li>The number of people served with individual and group Medicare Advantage offerings grew by 505,000 through the first half of 2025. Medicare Supplement plans contracted by 30,000, and Stand-Alone Part D plans decreased by 250,000.</li>
<li>Optum Health's revenue of $25.2 billion decreased 7% year-over-year, driven by the legacy customer contract revisions cited in the first quarter of 2025 and effects related to the Medicare Advantage funding cuts.</li>
<li>Earnings from operations were $636 million, compared to $1.9 billion in the year-ago quarter, and operating margins were 2.5% and 7.1%, respectively.</li>
</ul>
Guidance: UnitedHealth reestablished its fiscal year 2025 guidance, with adjusted earnings of at least&nbsp;$16 per share versus a consensus of&nbsp;$22.33 and sales&nbsp;guidance&nbsp;of&nbsp;$445.5 billion-$448 billion compared to the analyst estimate of $449.5 billion.
In May, UnitedHealth suspended its 2025 performance outlook.
It expected adjusted earnings of $26.00-$26.50 per share versus&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" rel="noreferrer noopener">prior guidance of $29.50-$30.00</a> per share, versus consensus of $29.73.
The full-year 2025 medical cost ratio is now expected to be 89.25% +/—25 basis points, with operating cost ratio expected to be 12.75% +/- 25 basis points.
For Optum Health: 2025 revenues are expected to be between $101.1 billion and $101.6 billion, a 4% decline from 2024, with earnings from operations of $3 billion—$3.1 billion below expectations of around $6.6 billion.
<ul class="wp-block-list">
<li>The number of patients served under fully accountable value-based care models is now expected to increase by around 300,000 to 5 million.</li>
</ul>
UnitedHealthcare&#8217;s full-year 2025 revenues are expected to range from $344 billion to $345.5 billion, growing more than 15% over 2024. Earnings from operations are expected to be in the range of $9.0 billion to $9.3 billion.
<ul class="wp-block-list">
<li>The number of people served with medical benefits is expected to increase by up to 1.135 million over 2024.</li>
<li>The number of people served with commercial benefits is expected to increase by up to 335,000, with growth of 720,000 within self-funded employer-sponsored offerings.</li>
<li>The number of people served with commercial insured offerings is expected to decline by 385,000, comprised of 180,000 contraction in individual insured offerings, of which 140,000 are on exchange products, and a decline of 205,000 in employer-sponsored group products.</li>
</ul>
During the earnings conference call, a UnitedHealth executive reportedly said the company will be more conservative with its footprint and may exit certain markets to manage its membership profile.
Price Action: UNH stock is down 4.5% at $269.41 on the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46680128/self-driving-cars-could-be-200-billion-market-by-2030-says-morgan-stanley" target="_blank" rel="noreferrer noopener">Self-Driving Cars Could Be $200 Billion Market By 2030, Says Morgan Stanley</a></li>
</ul>
Image: Shutterstock

UnitedHealth Misses Q2 Mark But Vows A Healthier 2026

Simpson Manufacturing shares are trading higher after the company reported Q2 financial results and beat its EPS and revenue estimates.

<a href="https://www.bloomberg.com/news/articles/2025-07-29/china-minister-meets-us-delegation-including-apple-in-beijing?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-29/china-minister-meets-us-delegation-including-apple-in-beijing?embedded-checkout=true</a>

AAPL

'China Minister Meets US Delegation Including Apple in Beijing'- Bloomberg

SANM

Sanmina shares are trading higher after the company reported better-than-expected Q3 financial results.

Herc Holdings shares are trading lower after the company reported a Q2 adjusted EPS miss.

Ecolab shares are trading lower after the company reported worse-than-expected Q2 adjusted EPS results.

SoFi Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) reported second-quarter financial results before the market open on Tuesday. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/07/b46682818/sofi-reports-second-quarter-2025-accelerates-net-revenue-growth-to-record-855-million-record-membe">from the quarter</a>.
Q2 Earnings: SoFi reported second-quarter revenue of $858.23 million, beating analyst estimates of $801.49 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported second-quarter adjusted earnings of 8 cents per share, beating estimates of 6 cents per share. 
Total revenue was up 44% year-over-year as fee-based revenue climbed 72%. Members grew 34% year-over-year to 11.7 million and products increased 34% year-over-year to 17.1 million. 
SoFi originated&nbsp;$8.8 billion&nbsp;in loans during the quarter, with personal loans up 66%, student loans up 35% and home loans up 92%. SoFi&#8217;s annualized charge-off rate decreased from&nbsp;3.31%&nbsp;to&nbsp;2.83%&nbsp;for personal loans.
The company ended the quarter with $2.12 billion in cash and cash equivalents. 
&#8220;We had an exceptional&nbsp;second quarter, driving durable growth and strong returns through our relentless focus on product innovation and brand building,&#8221; said Anthony Noto, CEO of SoFi.
&#8220;Looking forward, we are focusing on innovating faster than ever before to serve more of our members&#8217; needs and increasing our financial&nbsp;guidance&nbsp;for 2025.&#8221;
Guidance: SoFi raised its full-year 2025 revenue outlook from a range of $3.24 billion to $3.31 billion to a new target of approximately $3.38 billion versus estimates of $3.27 billion, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
SoFi also raised its full-year earnings forecast from a range of 27 cents to 28 cents per share to 31 cents per share versus estimates of 28 cents per share. 
The company expects to add at least 3 million new members in 2025, representing growth of approximately 30% year-over-year. 
SOFI Price Action: <a href="http://benzinga.com/quote/sofi" target="_blank" rel="noreferrer noopener">SoFi shares</a> were up 17.7% at $24.75 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/insights/options/25/07/46631529/sofi-technologiess-options-a-look-at-what-the-big-money-is-thinking">SoFi Technologies&#8217;s Options: A Look at What the Big Money is Thinking</a></li>
</ul>
Photo: Shutterstock.

SOFI

SoFi Technologies Stock Surges On 'Exceptional' Q2 Earnings, Raised Guidance

Press Releases

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma Attends FDA CEO Forum in Washington DC

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

Comments

Immix Biopharma

Immix Biopharma (IMMX) Opciones

Immix Biopharma (NASDAQ:IMMX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL